NCT03396211View on ClinicalTrials.gov

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

October 28, 2020

Study Completion Date

March 16, 2022

Conditions
Cancer
Interventions
DRUG

Apatinib

Apatinib tablets

DRUG

Nivolumab

Fixed dose of nivolumab given intravenously every 2 weeks

Trial Locations (1)

90403

Sarcoma Oncology Research Center, Santa Monica

Sponsors
All Listed Sponsors
lead

Elevar Therapeutics

INDUSTRY

NCT03396211 - A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer | Biotech Hunter | Biotech Hunter